Companies / Cullinan Therapeutics, Inc. / Activity
Activity — Cullinan Therapeutics, Inc.
60 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Prudential Financial Inc 13F manager | New | Common stock | $2.12M | +149K | 149,445 0.23% of shares | low |
| Q4 2025 as of | Bank of America Corp /De 13F manager | Trim | Common stock | $-2.18M | -211K -37.85% | 346,307 0.54% of shares | low |
| Q1 2026 as of | Schroder Investment Management Group 13F manager | Trim | Common stock | $-2.28M | -170K -49.45% | 173,740 0.27% of shares | low |
| Q2 2024 as of | Barclays PLC 13F manager | Add | Common stock | $2.74M | +157K +390.93% | 197,314 0.31% of shares | low |
| Q2 2026 as of | Deutsche Bank AG 13F manager | Trim | Common stock | $-3.71M | -204K -34.74% | 382,840 0.59% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Trim | Common stock | $-4.37M | -308K -48.69% | 324,111 0.50% of shares | low |
| Q1 2026 as of | Great Point Partners, LLC 13F manager | Trim | Common stock | $-4.75M | -334K -52.68% | 300,000 0.47% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | Common stock | $9.03M | +635K +153.30% | 1,049,581 1.63% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $15.16M | +832K +18.92% | 5,232,766 8.13% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $26.79M | +1.5M +66.96% | 3,668,627 5.70% of shares | medium |